April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Yüksel Ürün: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Mar 31, 2025, 11:43

Yüksel Ürün: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism

Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, posted on X:

“BREAKING from NEJM.

In cancer patients with Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is:
  • Noninferior to full-dose (5 mg BID) for VTE recurrence.
  • Lower bleeding risk (12.1% vs. 15.6%).
  • Safer extended anticoagulation, same protection.”

Jennifer A. Marks, Thoracic Oncologist at Georgetown Lombardi, shared this post on X, adding:

“Finally, the data for cancer-associated VTE is here! Despite some of us already doing this in other settings, I’m thankful to see this literature!”

“Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.”

Authors: Isabelle Mahé et al.

Yüksel Ürün: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism